Rilonacept
Rilonacept IIS 1604
Phase 1 small_molecule active
Quick answer
Rilonacept for Autoimmune Neurosensory Hearing Loss (ANSHL) is a Phase 1 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Autoimmune Neurosensory Hearing Loss (ANSHL)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active